PMID: 3384359Jun 1, 1988Paper

Effect and mechanism of action of isosorbide-5-mononitrate

Gut
P C HayesR Williams

Abstract

Nitrates have been shown to decrease portal pressure in cirrhotic patients with portal hypertension and this has been attributed to decreased portal venous resistance. We studied the effect and mechanism of action of oral administration of isosorbide-5-mononitrate (Is-5-Mn) (20 mg), which, unlike the dinitrate, does not require hepatic biotransformation to a vasoactive metabolite on portal and systemic haemodynamics in 11 patients with portal hypertension complicating cirrhosis. A significant reduction in portal pressure gradient (WHVP-FHVP) (from 23.9 (3.4) to 21.8 (3.4) mmHg: p less than 0.005) occurred 60 minutes after Is-5-Mn due entirely to a fall in WHVP, associated with decreased estimated liver blood flow (from 1940 (159) to 1639 (179) ml/min: p less than 0.05). Right atrial and pulmonary artery pressures and cardiac index fell significantly whilst mean arterial pressure remained unaffected. Heart rate and the calculated systemic vascular resistance index increased significantly. Significant correlations existed between the reduction in portal pressure gradient and fall in cardiac index (r = 0.65, p less than 0.05) and increase in systemic vascular resistance index (r = 0.72, p less than 0.02). The observed decrease in ...Continue Reading

References

Aug 31, 1985·British Medical Journal·J G FreemanC O Record
Jan 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A T Blei, J Gottstein
Jul 26, 1980·Lancet·D LebrecJ P Benhamou
Nov 1, 1982·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R J GroszmannE H Storer
Sep 1, 1982·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D LebrecJ P Benhamou

❮ Previous
Next ❯

Citations

Jun 3, 2000·Gastroenterology Clinics of North America·V A Luketic, A J Sanyal
Feb 24, 2001·Alimentary Pharmacology & Therapeutics·D Tripathi, P C Hayes
May 29, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J GournayJ P Galmiche
Jun 1, 1997·Baillière's Clinical Gastroenterology·J C García-Pagán, J Bosch
Sep 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y T TsaiK J Lo
Sep 22, 2001·Clinics in Liver Disease·V A Luketic
May 1, 1990·Journal of Hepatology·R Moreau, D Lebrec
Jan 1, 1993·Journal of Hepatology·J BoschJ Rodés
Feb 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J C Garcia-PagánJ Rodés
May 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J M SalmerónV Arroyo
Oct 1, 1992·Alimentary Pharmacology & Therapeutics·R D Grose, P C Hayes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.